A haemorrhagic stroke is a stroke that is caused by bleeding in or around the brain. Although they are less common than strokes that are caused by a blockage, they can be much more serious.
A panel of independent experts has decided that alteplase, a clot-busting drug often used to treat strokes is safe and effective under current guidelines.
Published in the journal Stroke, a new study suggests that a drug commonly used to treat rheumatoid arthritis may help reduce harmful inflammation in the brain after stroke. The study was funded by the Stroke Association.
Can a drug commonly used for gout improve recovery and prevention of further stroke for stroke survivors?
Thrombolysis, where drugs are injected into the blood to break up a blood clot, is one of the main treatments used to treat people who are having a stroke caused by a clot. Currently a drug called alteplase is used in thrombolysis. But the researchers think that another drug, called tenecteplase, may be more effective than alteplase. This study will investigate if this is the case.
This study will compare tenecteplase, a newer clot-busting drug, with alteplase, which is currently the routine treatment used in hospitals.
Led by the University of Nottingham, a new international study investigated whether patients with a spontaneous bleed in the brain (intracerebral haemorrhage) could benefit from this drug, if delivered as an emergency treatment. An intracerebral haemorrhage is a type of stroke.
In stroke survivors, does the clinical effectiveness of 6 months treatment with fluoxetine depend upon its effects on synaptic plasticity in the brain? Can a drug used for depression help stroke recovery by changing connections between brain cells?
The CROMIS-2 study investigated whether signs of small brain bleeds on routine brain scans can help us understand which ischaemic stroke patients with atrial fibrillation are at increased risk of a bleed in the brain when on anticoagulant ‘blood thinning’ drugs.